Safar Partners Leads Pirouette’s Investment Round with $5M+ Raised, Extending Opportunity for Public to Invest Alongside Renowned Investors like Y Combinator

Pirouette aims to use their patented technology to revolutionize the $600B injectable medicine market, making life-saving injections as easy as pushing a button

PORTSMOUTH, N.H.–(BUSINESS WIRE)–Pirouette, with their innovative auto-injector platform, announced they have surpassed $5M raised in their community investment round on Wefunder, prompting them to extend the round due to overwhelming demand. This extension gives the millions that this solution is designed to help more time to invest and accelerate the pathway to making it available – a rare opportunity to join alongside renowned institutional investors like Safar Partners, Liquid 2 Ventures, and Gaingels.


Led by a team of rocket scientists from MIT, Harvard Medical School, Harvard Business School, Clarkson University, General Electric, and NASA, Pirouette is set to revolutionize drug administration – simplifying life-saving injections like Epinephrine for severe allergies and Naloxone for opioid overdose. With 21 patents awarded and additional filings underway, the investment round has captured the attention of industry leaders and investors, recognizing Pirouette’s potential to disrupt the dinosaur injectables industry. The company’s mission to simplify injectable treatments aligns with the growing demand for patient-centric healthcare solutions – 93% of surveyed patients and 70% of surveyed prescribers are eager to switch to Pirouette’s patented epinephrine auto-injector when it is approved and becomes available.

“We are overjoyed by the enthusiasm and support from our community of investors,” says Conor Cullinane, PhD, CEO and Co-founder of Pirouette Medical. “With severe allergies on the rise and the opioid crisis escalating, this touches everyone, and the need for our innovative autoinjector has never been greater.”

Matthew Kane, The COO of Pirouette Medical added, “This funding is a crucial step towards bringing our groundbreaking device to market, aiming to enable life-saving medications that are within easy reach of those in need.”

Pirouette’s investment round is still open to the public for a limited time through Wefunder, the leading platform for early-stage retail investing, with an opportunity for anyone who is impacted or has a loved one who is impacted to invest and own a stake in the company.

For more information about Pirouette Medical and to participate in reimagining injections, visit wefunder.com/pirouette. Investments start from $100 and up to $500,000+.

About Pirouette Medical:

Pirouette Medical strives to revolutionize the healthcare industry with its innovative auto-injector technology by making life-saving injections as simple as pushing a button. Founded by experts from MIT, HMS, HBS, and Clarkson University, Pirouette aims to transform the $600 billion injectable medication market. With 21 patents awarded, backed by Y Combinator, Safar Partners, Liquid 2 Ventures, and Gaingels, Pirouette is dedicated to making critical treatments accessible and less intimidating for patients.

Contacts

Nina Ekmescic

Nina@capitaldept.com
6023448725